It is an R&D driven company which deals with research, development and manufacture of active pharmaceutical ingredients, nutritional ingredients, and other specialty products.
The shares of Symbiotec Pharmalab are currently trading at Rs. 1,156.40, Up by 0.13%.The company has a market capitalization of Rs. 7,428.01 crore. The stock’s 52 week high is Rs. 1,193.70 and its 52 week low is Rs. 934.20. In the past one month after the ipo it has delivered a return of 5.42%.
What’s The News?
Symbiotec Pharmalab reported its consolidated financial results for the quarter ended June 30, 2026. The company’s consolidated revenue from operations increased 7.4% YoY to Rs. 218.2 crore, compared with Rs. 203.2 crore in Q1 FY26.
Despite the growth in revenue, the company witnessed a significant decline in operating profitability. EBITDA fell 21.9% YoY to Rs. 45.2 crore, compared with Rs. 57.9 crore in the corresponding quarter last year.
Consequently, the EBITDA margin declined to 20.7% from 28.5% in Q1 FY26. At the bottom line, consolidated net profit declined 53% YoY to Rs. 14.1 crore, compared with Rs. 29.9 crore in Q1 FY26.
Higher Costs Impact Profitability
The most significant aspect of the quarter was the discrepancy between revenue growth and profits. While the revenue grew by approximately Rs. 15 crore YoY, various expenditure heads saw a higher rate of increase. The cost of employee benefits was Rs. 46.4 crore, whereas the depreciation and amortization cost was Rs. 21.8 crore. The finance costs of the firm were Rs. 6.2 crore for the quarter.
In addition to that, there was a decline in other incomes by Rs. 0.34 crore in Q1 FY27 from Rs. 26.41 crore in the same quarter last year. Consequently, the pre-tax profit fell to Rs. 17.5 crore from Rs. 44.8 crore in Q1 FY26, resulting in a net profit of Rs. 14.1 crore for the quarter.
API Business
The main source of revenue for Symbiotec, i.e., the API business, still constituted a dominant proportion of income for the quarter. The income from the API segment is estimated at around Rs. 215.3 crore, showing an increase of about 6% on a YoY basis, whereas the EBITDA from the API business reached around Rs. 65.8 crore.
New business initiatives of the company include injectable and biotech segments. The management believes that these new businesses will start generating revenues in 6-12 months.
CDMO Expansion
Symbiotec is also working on expanding its CDMO capabilities. Management has outlined a 600 KL CDMO capacity addition, which is backed by a customer agreement. The expansion is expected to support the company’s contract development and manufacturing business as it scales its operations.
Financial Performance
Looking at the quarterly results, the company’s consolidated revenue from operations stood at Rs. 218.2 crore in Q1 FY27, compared with Rs. 203.2 crore in Q1 FY26, registering a growth of around 7.4% YoY.
However, operating profitability declined during the quarter. EBITDA stood at Rs. 45.2 crore, compared with Rs. 57.9 crore in the corresponding quarter of the previous year, marking a decline of around 21.9% YoY. As a result, the EBITDA margin declined to 20.7% from 28.5%.
At the bottom line, consolidated net profit declined sharply by 53% YoY to Rs. 14.1 crore, compared with Rs. 29.9 crore in Q1 FY26. The PAT margin fell to around 6.5% from 14.7% a year earlier.
Overall, while the company maintained growth in revenue, the decline in operating margins significantly impacted profitability, resulting in a sharper fall in net profit during the quarter.
Investor Perspective
The financial performance for Q1 FY27 at Symbiotec Pharmalab is a contradictory one. The revenue growth of 7.4% YoY shows that there is still demand for the company’s primary pharmaceutical activities. Nonetheless, the steep fall in EBITDA and net profits suggests issues regarding profitability.
The company is simultaneously investing in new businesses and capacity, including the planned 600 KL CDMO expansion. The contribution from these initiatives will be an important factor to watch in the coming quarters. Management expects revenue from some of the new businesses to begin contributing within 6–12 months.
For investors tracking the company after its recent listing, key factors to monitor include recovery in EBITDA margins, the pace of CDMO expansion, contribution from new injectable and biotechnology businesses, and the ability of revenue growth to translate into higher consolidated profitability.
Company Overview
Symbiotec Pharmalab Limited is a research & development-led pharmaceutical and biotech organization that is focused on the manufacture of Active Pharmaceutical Ingredients (APIs), Nutritional and Specialty Ingredients.
The company has its operations in the domains of Organic Chemistry, Biotechnology and Complex Injectable products. The company has its manufacturing facilities located in Rau, Mhow and Pithampur of Madhya Pradesh and the company has its portfolio of over 60 APIs of corticosteroid and Steroidal Hormones.